Cardiff Oncology, Inc. (CRDF) stock forecast and price target
Price $0.73 · data as of November 13, 2026
12-month price target
Average target$6.28
Upside / downside+765.4%
Analysts6
ConsensusBuy
Low $1.20Average $6.28High $12.00
Gold marker: average target · white marker: today’s price ($0.73)
Analyst ratings
Strong buy 1Buy 2Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.56 | +19.3% | $360670 |
| Next fiscal year ends December 31, 2027 | $-0.52 | +6.1% | $320830 |
| Next quarter ends December 31, 2026 | $-0.12 | −12.1% | $48750 |
| Quarter after ends March 31, 2027 | $-0.12 | +30.6% | $87500 |
Consensus of the analysts covering Cardiff Oncology, updated daily. In the last 30 days 4 estimates were raised and 0 lowered.
Frequently asked questions
What is the Cardiff Oncology stock price target?
The average 12-month target from 6 analysts is $6.28, 765.4% above the current price of $0.73 Targets range from $1.20 to $12.00.
Is Cardiff Oncology a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 2 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Cardiff Oncology expected to earn?
Analysts expect EPS of $-0.56 for the fiscal year ending December 31, 2026 and $-0.52 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.